Correction to Lancet Gastroenterol Hepatol 2025; 10: 634–47

The Lancet. Gastroenterology & hepatology 2026 Open access

Read full text
DOI: 10.1016/s2468-1253(26)00055-5
Cited by: 0

Abstract

22-33-in figure 3 of this Article, the first row of numbers of participants at each timepoint under Treatment in part A should be labelled Placebo and the second row should be labelled Linerixibat.This correction has been made as of March 11, 2026.

Publication details

Journal / source
The Lancet. Gastroenterology & hepatology
Volume
11
Issue
4
Pages
e6–e6
Publication date
11 March 2026
Language
EN